[Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
The data on prophylaxis efficacy of the Palivizumab (synagis) against respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia are shown in the article. No side-effects, good tolerance and decrease of the frequency of bronchopulmonary dysplasia relapses and other viral diseases in whole in such children were registered.